Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 May;34(5):1065-1073.
doi: 10.1111/jdv.16204. Epub 2020 Apr 30.

Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

I Poizot-Martin  1 , V Obry-Roguet  2 , C Duvivier  3   4   5   6 , C Lions  2 , T Huleux  7 , C Jacomet  8 , T Ferry  9 , A Cheret  10   11 , C Allavena  12 , F Bani-Sadr  13 , R Palich  14   15 , A Cabié  16   17   18 , A Fresard  19 , P Pugliese  20 , P Delobel  21 , I Lamaury  22 , L Hustache-Mathieu  23 , S Brégigeon  2 , A Makinson  24 , D Rey  25 ; Dat'AIDS study group
Collaborators, Affiliations
Multicenter Study

Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

I Poizot-Martin et al. J Eur Acad Dermatol Venereol. 2020 May.

Abstract

Background: Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people.

Objective: To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage.

Methods: Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (≤50 or >50) copies/mL.

Results: Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naïve patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL ≤50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis.

Limitations: Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected.

Conclusion: Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL ≤50 cp/mL remain to be explored.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median CD4 T‐cell count in 209 patients with Kaposi sarcoma according to ART exposure at time of KS diagnosis in the French DAT’AIDS cohort between 2010 and 2015.
See this image and copyright information in PMC

References

    1. Yanik EL, Achenbach CJ, Gopal S et al Changes in clinical context for Kaposi's sarcoma and Non‐Hodgkin Lymphoma among people with HIV infection in the United States. J Clin Oncol 2016; 34: 3276–3283. - PMC - PubMed
    1. Yarchoan R, Uldrick TS. HIV‐associated cancers and related diseases. N Engl J Med 2018; 378: 1029–1041. - PMC - PubMed
    1. Klingenberg R‐E, Esser S, Brockmeyer NH et al Profile of Kaposi sarcoma patients in the competence network HIV/AIDS. Hautarzt 2018; 69: 143–148. - PubMed
    1. Pugliese P, Cuzin L, Cabié A et al A large French prospective cohort of HIV‐infected patients: the Nadis Cohort. HIV Med 2009; 10: 504–511. - PubMed
    1. Poizot‐Martin I, Makinson A, Protopopescu C et al Kaposi sarcoma incidence between 2010‐2015 in the French Dat'AIDS cohort. In: Vol 0275. Seattle: Conference on Retroviruses and Opportunistic Infections; 2019:0275.

Publication types

MeSH terms